Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Jerome Stevens Unithroid Marketing Will Emphasize NDA Approval

  • News

Executive Summary

Unithroid's status as an NDA-approved drug will be the focal point of Jerome Stevens Pharmaceuticals' marketing efforts for the levothyroxine tablets.

You may also be interested in...



Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years

Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says

Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years

Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says

King Levoxyl NDA Approval Anticipated In May Ahead of FDA August Deadline

King expects FDA to approve its Levoxyl NDA by the end of May, the company's President and Chief Operating Officer Jeff Gregory said during a conference call Feb. 20.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS036548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By